A Q-TWiST analysis of adjuvant chemotherapy in non-small cell lung cancer (NSCLC) in the NCIC CTG JBR.10 trial

被引：0
|
作者：
Jang, R. W.
Le Maitre, A.
Ding, K.
Winton, T. L.
Bezjak, A.
Seymour, L.
Shepherd, F. A.
Leighl, N. B.
机构：
[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[2] Natl Canc Inst Canada, Kingston, ON, Canada
[3] Univ Alberta, Edmonton, AB, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.6535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6535
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer:: Analysis of NCIC JBR.10
    Seve, Pascal
    Lai, Raymond
    Ding, Keyue
    Winton, Timothy
    Butts, Charles
    Mackey, John
    Dumontet, Charles
    Dabbagh, Laith
    Aviel-Ronen, Sarit
    Seymour, Lesley
    Whitehead, Marlo
    Tsao, Ming-Sound
    Shepherd, Frances A.
    Reiman, Tony
    CLINICAL CANCER RESEARCH, 2007, 13 (03) : 994 - 999
  • [2] Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: The JBR.10 trial experience
    Gauthier, I.
    Ding, K.
    Winton, T.
    Shepherd, F. A.
    Livingston, R.
    Johnson, D. H.
    Rigas, J. R.
    Whitehead, M.
    Graham, B.
    Seymour, L.
    LUNG CANCER, 2007, 55 (03) : 357 - 363
  • [3] An economic analysis of National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) JBR.10, a randomized trial of adjuvant vinorelbine plus cisplatin versus observation in early stage non-small cell lung cancer (NSCLC).
    Ng, R.
    Mittmann, N.
    Florescu, M.
    Shepherd, F. A.
    Salvarrey, A.
    Seymour, L.
    Winton, T.
    Evans, B.
    Leighl, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 402S - 402S
  • [4] Pathologic determinants of survival for adjuvant treatment of stage IB non-small cell lung cancer (NSCLC): an analysis of the National Cancer Institute of Canada (NCIC) and Intergroup Study JBR.10
    Strevel, Elizabeth L.
    Ding, Keyue
    Seymour, Lesley
    Tsao, Ming S.
    Le Maitre, Aurelie
    Shepherd, Frances A.
    Burkes, Ronald L.
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S333 - S334
  • [5] Quality of life (QOL) impact of adjuvant chemotherapy for early stage non- small cell lung cancer (NSCLC): Final analysis of JBR.10 randomized trial
    Bezjak, A.
    Lee, C. W.
    Ding, K.
    Winton, T.
    Brundage, M.
    Graham, B.
    Whitehead, M.
    Seymour, L.
    Shepherd, F. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] The significance of K-ras mutations in the Intergroup JBR.10 Trial on adjuvant chemotherapy in completely resected early stage non-small cell lung cancer (NSCLC) patients
    Tsao, M
    Zhu, C
    Livingston, R
    Johnson, D
    Gandara, D
    Viallet, J
    Ding, K
    Seymour, L
    Winton, T
    Shepherd, F
    LUNG CANCER, 2005, 49 : S41 - S41
  • [7] Adjuvant chemotherapy in non-small cell lung cancer (NSCLC)
    Felip, E.
    Cedres, S.
    Peralta, S.
    Prat, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 143 - 146
  • [8] A COST-EFFECTIVENESS ANALYSIS OF THE 15-GENE EXPRESSION SIGNATURE IN GUIDING ADJUVANT CHEMOTHERAPY IN EARLY STAGE NON-SMALL CELL LUNG CANCER BASED ON THE JBR.10 TRIAL
    Wong, Kit Man
    Li, Suzanne
    Ding, Keyue
    Bradbury, Penelope
    Tsao, Ming-Sound
    Shepherd, Frances A.
    Chung, Carmen
    Ng, Raymon
    Seymour, Lesley
    Leighl, Natasha B.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S304 - S304
  • [9] Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA
    Graziano, Stephen L.
    Azougagh, Said
    Vollmer, Robin
    Kratzke, Robert
    Popper, Helmut
    Filipits, Martin
    Tsao, Ming
    Seymour, Lesley
    Rosell, Rafael
    Taron, Miquel
    Pignon, Jean-Pierre
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S506 - S506
  • [10] Do hemoglobin (Hb) levels influence outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non small cell lung cancer (NSCLC)? The JBR.10 trial experience
    Gauthier, I
    Ding, K
    Winton, T
    Shepherd, F
    Livingston, R
    Johnson, D
    Rigas, J
    Whitehead, M
    Graham, B
    Seymour, L
    LUNG CANCER, 2005, 49 : S280 - S280
12345